C. Ravoet

发表

Non‐surgical treatment of hepatocarcinoma

H. Bleiberg, B. Gerard, C. Ravoet, 1993, Journal of surgical oncology. Supplement.

Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.

M. André, K. van Eygen, W. Pluymers, 2014, Leukemia research.

Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.

A. Stamatoullas, P. Fenaux, N. Vey, 2010, Leukemia research.

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

H. Dombret, A. Stamatoullas, P. Greenberg, 2008, Blood.

Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine

M. Lübbert, M. André, G. Verhoef, 2001, British journal of haematology.

DNA demethylating therapy in MDS: The experience with 5-AZA-2 '-deoxycytidine (decitabine).

M. André, A. Ferrant, M. Luebbert, 1999 .

Tumour stimulating effects of recombinant human interleukin-6

M. Piccart, J. Sculier, P. Lacor, 1994, The Lancet.

Genes encoding tumor-specific antigens are expressed in human myeloma cells.

F. Brasseur, M. André, T. Boon, 1999, Blood.

Myeloma Cells Genes Encoding Tumor-Specific Antigens Are Expressed in Human

F. Brasseur, T. Boon, C. Doyen, 2013 .

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5 q deletion : results of a phase 2 study

A. Stamatoullas, P. Fenaux, L. Adès, 2009 .

P135 Has treatment with EPO+/-G-CSF an impact on progression to AML and survival in low/int-1-risk MDS? A comparison between French-EPO patients and the IMRAW database

H. Dombret, P. Greenberg, P. Fenaux, 2007 .

Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey

V. Voelter, D. Deeren, K. Theunissen, 2015, Acta clinica Belgica.

Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes , acute myeloid leukaemia , or chronic myelomonocytic leukaemia : results of a real-life , non-interventional postmarketing survey

V. Voelter, D. Deeren, K. Theunissen, 2015 .

Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM

A. Stamatoullas, P. Fenaux, L. Adès, 2012, British journal of haematology.

Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts

J. Bourhis, P. Fenaux, V. Ribrag, 2003, Leukemia.

Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40–CD40L interactions with T helper cells

L. Boon, C. Verfaillie, G. Verhoef, 2007, Leukemia.

Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study

P. Martiat, M. André, L. Debusscher, 2008, Annals of Hematology.

A Four-Parameter Index of Marrow Dysplasia Has Predictive Value for Survival in Myelodysplastic Syndromes

W. Dewé, Y. Beguin, N. Schaaf, 2000, Leukemia & lymphoma.

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

H. Dombret, A. Stamatoullas, L. Mannone, 2006 .

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

A. Stamatoullas, P. Fenaux, L. Adès, 2007 .

Simplification of the blood stem cell transplantation (BSCT) procedure: large volume apheresis and uncontrolled rate cryopreservation at –80°C

E. Dupont, O. Pradier, W. Feremans, 1996, European journal of haematology.

Long-term follow-up of autologous peripheral blood stem cell transplantation in the treatment of a patient with acute panmyelosis with myelofibrosis.

M. André, I. Ahmad, D. Bron, 2006, Haematologica.

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.

M. Piccart, J. Sculier, A. Awada, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of uncontrolled freezing and long-term storage of peripheral blood stem cells at −80 °C on haematopoietic recovery after autologous transplantation. Report from two centres

A. Delannoy, J. Bay, O. Tournilhac, 2014, Bone Marrow Transplantation.

Clinical evidence for an engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation.

A. Delannoy, A. Kentos, W. Feremans, 1996, Bone marrow transplantation.

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

M. Lübbert, M. André, G. Verhoef, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Contribution of Flow Cytometry to the Diagnosis of Malignant and Non Malignant Conditions in Lymph Node Biopsies

M. Dehon, A. Delannoy, M. Peny, 2004, Leukemia & lymphoma.

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.

A. Stamatoullas, P. Fenaux, L. Adès, 2009, Blood.

Translocation of BCL2 and BCL6 to the same immunoglobulin heavy chain locus in a case of Follicular Lymphoma

Y. Gillerot, J. Hamels, A. Delannoy, 2005, Leukemia & lymphoma.

Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes

W. Pluymers, I. Abraham, M. Delforge, 2011, Annals of Hematology.

Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine

M. Lübbert, M. André, G. Verhoef, 2001, British Journal of Haematology.

Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).

C Sebban, G. Salles, R. Bouabdallah, 2000, Blood.

LENALIDOMIDE IN RELAPSED REFRACTORY MYELOMA PATIENTS: IMPACT OF PREVIOUS RESPONSE TO BORTEZOMIB AND THALIDOMIDE ON TREATMENT EFFICACY. RESULTS OF A MEDICAL NEED PROGRAM IN BELGIUM

R. Schots, A. Kentos, M. Delforge, 2011, Acta clinica Belgica.

Optimal blood stem cell mobilization using 10 μg/kg granulocyte colony‐stimulating factor (G‐CSF) alone for high‐dose melphalan intensification in multiple myeloma: An intrapatient controlled study

E. Dupont, O. Pradier, W. Feremans, 1994, American journal of hematology.

Predictive value of the steady-state peripheral blood progenitor cell (PBPC) counts for the yield of PBPC collected by leukapheresis after mobilization by granulocyte colony-stimulating factor (G-CSF) alone or chemotherapy and G-CSF.

M. Dehon, A. Delannoy, B. Husson, 1996, Blood.

MANAGEMENT OF MYELODYSPLASTIC SYNDROMES IN ADULTS: GUIDELINES FROM THE BELGIAN HAEMATOLOGICAL SOCIETY1

M. Delforge, C. Graux, D. Selleslag, 2013, Acta clinica Belgica.

Thromboembolism in inflammatory bowel disease.

F. Heller, J. Henrion, S. De maeght, 1999, Acta gastro-enterologica Belgica.

CA-125 in primary mediastinal B-cell lymphoma with sclerosis.

W. Feremans, C. Ravoet, J. Dargent, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hematopoietic growth factors in drug-induced agranulocytosis.

A. Delannoy, C. Ravoet, 1995, Leukemia.

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

A. Stamatoullas, P. Fenaux, L. Adès, 2013, Leukemia.

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

R. Greil, H. Döhner, M. Minden, 2015, Blood.

Cytogenetic remissions in high-risk myelodysplastic syndrome: Results in 124 patients treated with low-dose 5-aza-2 '-deoxycytidine (Decitabine), a DNA methylation inhibitor.

M. Lübbert, M. André, A. Ferrant, 2000 .